OR WAIT null SECS
Growth and Advancements in Fill/Finish
Employing novel technologies and more patient-centric approaches
Delving into Biopharmaceutical Development and Manufacturing
Quality Considerations in Changing Excipient Providers
October 21, 2022
AAPS will exclusively advise RX Global on scientific focus areas for Interphex 2023, which is set to take place at the Javits Center in New York City next spring.
Aenova Group and Microcaps are partnering to enable new customized formulations for product development and life cycle management solutions.
The agency has recommended approval of Comirnaty and Spikevax for children from six months of age.
The agency has recommended authorization of the Spikevax COVID-19 vaccine that targets the Omicron variants BA.4 and BA.5.
October 19, 2022
Gilead and MacroGenics will work together on bispecific antibodies for the treatment of blood cancers.
Ebvallo (tabelecleucel) would be the first EMA-approved therapy for patients with relapsed or refractory Epstein-Barr virus positive post-transplant lymphoproliferative disease.
Takeda’s dengue vaccine is designed to prevent disease caused by virus serotypes 1, 2, 3, and 4 in individuals four and older.
October 18, 2022
Product safety and security are paramount when it comes to container closures.
In this episode, Ana Ladino provides expert insight into novel excipients in the current and future drug development landscape.
October 16, 2022
Patient centricity is driving change in drug discovery and development, leading to a a new dawn in therapeutics.